Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity

Nature Medicine

Volumn 1, Issue 12, 1995, Pages 1297-1302

  Mayordomo, J I ^a   Zorina, T ^a   Storkus, W J ^a   Zitvogel, L ^a   Celluzzi, C ^a   Falo, L D ^a   Melief, C J ^b   Ildstad, S T ^a   Kast, W Martin ^b   Deleo, A B ^a   Lotze, M T ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE; TUMOR VACCINE;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMAL; ANTIGEN PRESENTATION; BONE MARROW CELLS; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; FEMALE; HUMAN; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; NEOPLASM PROTEINS; SARCOMA, EXPERIMENTAL; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; VACCINES, SYNTHETIC;

EID: 0028793675     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1295-1297     Document Type: Article

References (38)

1. Pardoll, D. Tumour antigens: A new look for the 1990s. Natur 369, 357-358 (1994)
2. Grabbe, S., Beissert, S., Schwartz, T. & Granstein, R. D. Dendritic cells as initiators of tumor immune responses: A possible strategy for tumor immunotherapy? Immun. Toda 16, 116-120 (1995).
3. vGulłino, M., Sachs, D. H. & Katz, S. I. la antigens in mouse skin are predominantly expressed on Langerhans cells. J. Immun 123, 784-787 (1979).
4. Razi-Wolf, Z., Falo, L. D. & Reiser, H. Expression and function of the costimulatory molecule B7 on murine Langerhans cells: Evidence for an alternative CTLA-4 ligand. Eur J. Immun 24, 805-811 (1994).
5. Inaba, K. et al. Identification of proliferating dendritic cell progenitors in mouse blood. J. exp. Med 175, 1157-1167 (1992).
6. Inaba, K. et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. /. exp. Med 176, 1693-1702 (1992).
7. Caux, C., Dezutter-Dambuyant C., Schmitt D. & Banchereau J. GM-CSF and TNFα cooperate in the generation of dendritic Langerhans cells. Natur 360, 258-261 (1992).
8. Caux, C. et al. Potentiation of early hematopoiesis by TNF alpha is followed by inhibition of granulopoietic differentiation and proliferation. Bloo 78, 635-644 (1991).
9. Koch, F. et al. Tumor necrosis factor α maintains the viability of murine epidermal Langerhans cells in culture, but in contrast to granulocyte/macrophage colony-stimulating factor, without inducing their functional maturation. J. exp. Med 171, 159-171 (1990).
10. Romani, N. et al. Proliferating dendritic cell progenitors in human blood. J. exp. Med 180, 83-93 (1994).
11. Sallusto, F. & Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin-4 and downregulated by tumor necrosis factor alpha. J. exp. Med 179, 1109-1118 (1994).
12. Zorina, T. et al. Culture of dendritic cells from murine bone marrow supplemented with GM-CSF and TNF-alpha. J. Immunother 16, 247 (1994).
13. Lanier, L. L. et al. CD80(B7) and CD86(B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J. Immun 154, 97-105 (1995).
14. Caux, C. et al. B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells. J, exp. Med 180, 1841-1847 (1994).
15. Mandelboim, O. et al. CTL induction by a tumour-associated antigen octapep-tide derived from a murine lung carcinoma. Natur 369, 67-71 (1994).
16. Feltkamp, M. C. W, et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immun 23, 2242-2249 (1993).
17. Falk, K., Rotzschke, O., Stevanovic, S., Jung, G. & Rammensee, H.-G. Allele-specific models revealed by sequencing of self-peptides eluted from MHC molecules. Natur 351, 290-296 (1991).
18. Falo, L. D., Kovacsovics-Bankowski, M., Thompson, K, & Rock, K. L. Targeting antigen into the phagocytic pathway in viv induces protective tumour immunity. Nature Med 1, 649-653 (1995).
19. Porgador, A. & Gilboa, E. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J. exp. Med 182, 255-260 (1995).
20. Gyure, L. A., Barfoot, R., Denham, S. & Hall, J. G. Immunity to a syngeneic sarcoma induced in rats by syngeneic lymph cells exposed to the tumour either in viv or in vitro. Br J. Cance 55, 17-20 (1987).
21. Knight, S. C., Hunt, R., Dore, C. & Medawar, P. B. Influence of dendritic cells on tumor growth. Proc. natn. Acad. Sci. U. S. A 82, 4495-4497 (1985).
22. Caux, C., Liu, Y-L. & Banchereau, J. Recent advances in the study of dendritic cells and follicular dendritic cells. Immun. Toda 16, 2-4 (1995).
23. Grabbe, S. et al. Tumor antigen presentation by murine epidermal cells. J. Immun 146, 3656-3661 (1991).
24. Fłamand, V. et al. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance ím vivo. Eur. J. Immun 24, 605-610 (1994).
25. Hsu, F. J. et al. Antigen-pulsed dendritic cells are effective in inducing immune responses in patients with B-cell lymphoma. Bloo 84, 520a (1994)
26. Kast, W. M., Boog, C. J. P., Roerp, B. O., Voordouw, A. C. & Melief, C. J. P. Failure or success in the restoration of virus-specific cytotoxic T lymphocyte response defects by dendritic cells. J. Immun 140, 3186-3193 (1988).
27. Mizoguchi, H. et al. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Scienc 258, 1795-1798 (1992).
28. Pan, Z.-K., Ikonomidis, G., Lazenby, A., Pardoll, D. & Paterson, Y. A recombinant Listeria monocytogene vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours. Nature Med 1, 471-177 (1995).
29. Aichele, P., Brduscha-Riem, K., Zinkernagel, R. M., Hengartner, H. & Pircher, H. T cell priming versus T cell tolerance induced by synthetic peptides. J. exp. Med 182, 261-266 (1995).
30. Jenkins, M. K. The ups and downs of T cell costimulation. Immunit 1, 443-446 (1994).
31. Bellone, M. et al. In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen-presenting cells. Eur J. Immun 24, 2691-2698 (1994).
32. Frassanito, M. A. et al. Identification of Meth A sarcoma-derived class I major histocompatibility complex-associated peptides recognized by a specific CD8+ cytotoxic T lymphocyte. Cancer Res 55, 124-128 (1995).
33. Storkus, W. J. & Lotze, M. T. Biology of tumor antigens: Tumor antigens recognized by immune cells. In: Biologic Therapy of Cancer 2nd edn (eds DeVita, V. T., Heilman, S. & Rosenberg, S. A. ) 64—77 (Lippincott, Philadelphia, 1995).
34. Peoples, G. E. et al. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc. natn. Acad. Sci. U. S. A. 92, 432-436 (1995).
35. Bosch, F. X. et al. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. J. natn. Cancer Inst 87, 796-802 (1995).
36. Moore, M. W., Carbone, F. R. & Bevan, M. J. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cel 54, 777-785 (1988).
37. Takahashi, H., Nakagawa, Y., Yokomuro, K., & Berzofsky, J. A. Induction of CD8+ cytotoxic T lymphocytes by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells. Int. Immun 5, 849-857 (1993).
38. 2-microglobulin as an adjuvant. J. Immun 150, 1244-1252 (1993).